KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Exelixis (EXEL) Cash & Equivalents (2016 - 2026)

Historic Cash & Equivalents for Exelixis (EXEL) over the last 17 years, with Q1 2026 value amounting to $482.5 million.

  • Exelixis' Cash & Equivalents rose 12196.21% to $482.5 million in Q1 2026 from the same period last year, while for Jan 2026 it was $482.5 million, marking a year-over-year increase of 12196.21%. This contributed to the annual value of $482.5 million for FY2026, which is 12196.21% up from last year.
  • According to the latest figures from Q1 2026, Exelixis' Cash & Equivalents is $482.5 million, which was up 12196.21% from $376.3 million recorded in Q4 2025.
  • Exelixis' 5-year Cash & Equivalents high stood at $723.3 million for Q2 2022, and its period low was $164.4 million during Q3 2025.
  • For the 5-year period, Exelixis' Cash & Equivalents averaged around $395.8 million, with its median value being $386.6 million (2023).
  • Its Cash & Equivalents has fluctuated over the past 5 years, first plummeted by 5727.29% in 2024, then surged by 12196.21% in 2026.
  • Quarter analysis of 5 years shows Exelixis' Cash & Equivalents stood at $501.2 million in 2022, then plummeted by 47.53% to $263.0 million in 2023, then dropped by 1.77% to $258.3 million in 2024, then surged by 45.66% to $376.3 million in 2025, then rose by 28.22% to $482.5 million in 2026.
  • Its Cash & Equivalents stands at $482.5 million for Q1 2026, versus $376.3 million for Q4 2025 and $164.4 million for Q3 2025.